A Phase 1 interventional study of Teduglutide and Syringe Injection in Healthy Volunteers, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-04.
Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same fixed dose delivered by the pen injector in healthy participants.
This is a 2-period crossover study and consists of two cohorts. Cohort 1 consists of participant's with greater than or equal to (>=) 40.0 kilogram (kg) to lesser than or equal to (\<=) 75.0 kg of weight and Cohort 2 consists of participant's with greater than (>) 75.0 kg to \<= 120.0 kg of weight. Participants in each cohort will be randomized to 1 of 2 treatment sequences AB or BA. Randomization will be stratified by injection site (i.e., thigh, abdomen, and arm) within each cohort.
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
First submitted after Shire became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Within 30 days prior to the first dose of teduglutide:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Teduglutide, 3 mg, subcutaneous (SC) injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A1), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B1). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants with \>=40.0 kg to \<=75.0 kg of weight were included in Cohort 1.
Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector
Teduglutide, 3 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B1), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A1). A Washout Period of 7 days was maintained between the Treatment Periods 1 and 2. Participants with \>=40.0 kg to \<=75.0 kg of weight were included in Cohort 1.
Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector
Teduglutide, 4 mg, SC injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A2), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.
Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector
Teduglutide, 4 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B2), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.
Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector
Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
Also known as: TAK-633
Teduglutide was administered using syringe.
Teduglutide was administered using pen injector.
Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Maximum Observed Plasma Concentration (Cmax) of Teduglutide
Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide by Injection Site
AUC0-last of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Maximum Observed Plasma Concentration (Cmax) of Teduglutide by Injection Site
Cmax of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide by Injection Site
AUC0-infinity of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Time of First Occurrence of Maximum Observed Plasma Concentration (Cmax) [Tmax] of Teduglutide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Terminal Disposition Phase Rate Constant (Lambda z) of Teduglutide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Terminal Disposition Phase Half-Life (t1/2z) of Teduglutide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Apparent Total Body Clearance (CL/F) of Teduglutide
CL/F for extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Apparent Volume of Distribution (Vz/F) of Teduglutide
Vz/F associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. Number of participants with TEAEs included injection site reactions and injection site injury assessments.
Time frame: From the start of study drug administration up to follow-up (up to 42 days)
Number of Participants With Clinically Significant Change in Vital Signs
Vital signs included body temperature, respiratory rate, blood pressure, and heart rate.
Time frame: From the start of study drug administration up to follow-up (up to 42 days)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Clinical laboratory assessments included hematology, serum chemistry, coagulation, and urinalysis. Changes in laboratory values may be considered as AE if they were judged to be clinically significant.
Time frame: From the start of study drug administration up to follow-up (up to 42 days)
Number of Participants With Clinically Significant Changes in Physical Examinations
Physical examination included examination of respiratory, cardiovascular, and gastrointestinal system.
Time frame: From the start of study drug administration up to follow-up (up to 42 days)
Number of Participants With Device Malfunction
Number of participants with device malfunction was assessed and reported. The site staff reported any malfunctions whilst using the device.
Time frame: Day 1
Participants took part in the study at 1 investigative site in the United States from 13 January 2021 to 20 August 2021.
| Milestone | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) |
|---|---|---|---|---|
| Started | 16 | 16 | 16 | 16 |
| Completed | 16 | 16 | 16 | 16 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) |
|---|---|---|---|---|
| Started | 16 | 16 | 16 | 16 |
| Completed | 16 | 16 | 16 | 16 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) |
|---|---|---|---|---|
| Started | 16 | 16 | 16 | 16 |
| Completed | 16 | 15 | 15 | 16 |
| Not completed | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| ng*hour/mL | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide | 217.2 ± 21.0 | 237.2 ± 22.1 | 221.9 ± 21.2 | 253.0 ± 21.4 |
Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Teduglutide | 33.90 ± 37.7 | 33.31 ± 37.6 | 31.99 ± 34.8 | 29.58 ± 32.6 |
| ng*hr/mL | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide | 227.6 ± 21.1 | 249.2 ± 20.8 | 227.1 ± 20.8 | 268.2 ± 22.2 |
AUC0-last of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.
| ng*hr/mL | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Abdomen | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Arm | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Thigh | Cohort 1 (Teduglutide 3 mg): Pen Injector in Abdomen | Cohort 1 (Teduglutide 3 mg): Pen Injector in Arm | Cohort 1 (Teduglutide 3 mg): Pen Injector in Thigh | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Abdomen | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Arm | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Thigh | Cohort 2 (Teduglutide 4 mg): Pen Injector in Abdomen | Cohort 2 (Teduglutide 4 mg): Pen Injector in Arm | Cohort 2 (Teduglutide 4 mg): Pen Injector in Thigh |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide by Injection Site | 241.2 ± 14.0 | 205.8 ± 29.1 | 202.2 ± 14.4 | 277.6 ± 9.1 | 216.6 ± 27.8 | 215.2 ± 16.7 | 219.6 ± 17.2 | 222.6 ± 27.9 | 224.1 ± 20.3 | 239.5 ± 19.0 | 277.3 ± 23.3 | 246.4 ± 21.3 |
Cmax of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.
| ng/mL | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Abdomen | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Arm | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Thigh | Cohort 1 (Teduglutide 3 mg): Pen Injector in Abdomen | Cohort 1 (Teduglutide 3 mg): Pen Injector in Arm | Cohort 1 (Teduglutide 3 mg): Pen Injector in Thigh | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Abdomen | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Arm | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Thigh | Cohort 2 (Teduglutide 4 mg): Pen Injector in Abdomen | Cohort 2 (Teduglutide 4 mg): Pen Injector in Arm | Cohort 2 (Teduglutide 4 mg): Pen Injector in Thigh |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Teduglutide by Injection Site | 40.84 ± 29.7 | 31.66 ± 41.6 | 29.02 ± 35.2 | 43.65 ± 20.7 | 28.73 ± 43.9 | 27.91 ± 27.3 | 26.86 ± 25.9 | 38.28 ± 43.8 | 32.97 ± 25.0 | 28.14 ± 30.4 | 32.33 ± 33.8 | 28.73 ± 35.5 |
AUC0-infinity of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.
| ng*hr/mL | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Abdomen | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Arm | Cohort 1 (Teduglutide 3 mg): Syringe Injection in Thigh | Cohort 1 (Teduglutide 3 mg): Pen Injector in Abdomen | Cohort 1 (Teduglutide 3 mg): Pen Injector in Arm | Cohort 1 (Teduglutide 3 mg): Pen Injector in Thigh | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Abdomen | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Arm | Cohort 2 (Teduglutide 4 mg): Syringe Injection in Thigh | Cohort 2 (Teduglutide 4 mg): Pen Injector in Abdomen | Cohort 2 (Teduglutide 4 mg): Pen Injector in Arm | Cohort 2 (Teduglutide 4 mg): Pen Injector in Thigh |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide by Injection Site | 246.6 ± 13.2 | 213.0 ± 29.5 | 218.6 ± 18.7 | 282.3 ± 9.1 | 229.6 ± 26.8 | 229.2 ± 18.6 | 224.7 ± 17.6 | 228.2 ± 27.1 | 228.7 ± 20.0 | 247.0 ± 19.7 | 296.8 ± 24.4 | 268.1 ± 20.9 |
| hour | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Time of First Occurrence of Maximum Observed Plasma Concentration (Cmax) [Tmax] of Teduglutide | 4.002 (2.00 to 8.06) | 4.001 (0.50 to 8.05) | 4.999 (2.01 to 8.04) | 4.507 (2.00 to 12.00) |
| 1/hr | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Terminal Disposition Phase Rate Constant (Lambda z) of Teduglutide | 0.4055 ± 51.2 | 0.4191 ± 41.0 | 0.3971 ± 41.8 | 0.3236 ± 48.1 |
| hour | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Terminal Disposition Phase Half-Life (t1/2z) of Teduglutide | 1.930 ± 1.1070 | 1.797 ± 0.8341 | 1.903 ± 0.9107 | 2.385 ± 1.2292 |
CL/F for extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.
| Liter(L)/hr | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Apparent Total Body Clearance (CL/F) of Teduglutide | 13.48 ± 3.2060 | 12.31 ± 2.9332 | 17.97 ± 3.5737 | 15.27 ± 3.5042 |
Vz/F associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.
| L | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Teduglutide | 36.85 ± 18.837 | 31.86 ± 15.382 | 49.84 ± 27.394 | 51.01 ± 23.867 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. Number of participants with TEAEs included injection site reactions and injection site injury assessments.
| Participants | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 13 | 10 | 9 | 5 |
Vital signs included body temperature, respiratory rate, blood pressure, and heart rate.
| Participants | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change in Vital Signs | 0 | 0 | 0 | 0 |
Clinical laboratory assessments included hematology, serum chemistry, coagulation, and urinalysis. Changes in laboratory values may be considered as AE if they were judged to be clinically significant.
| Participants | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 | 0 | 0 | 0 |
Physical examination included examination of respiratory, cardiovascular, and gastrointestinal system.
| Participants | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examinations | 0 | 0 | 0 | 0 |
Number of participants with device malfunction was assessed and reported. The site staff reported any malfunctions whilst using the device.
| Participants | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| Number of Participants With Device Malfunction | 0 | 0 | 0 | 0 |
Collected over From the start of study drug administration up to follow-up (up to 42 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | 0/32 (0%) | 0/32 (0%) | 13/32 (40.6%) |
| Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | 0/32 (0%) | 0/32 (0%) | 10/32 (31.3%) |
| Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | 0/32 (0%) | 0/32 (0%) | 9/32 (28.1%) |
| Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) | 0/32 (0%) | 0/32 (0%) | 1/32 (3.1%) |
| Event | Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) | Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) | Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) | Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/32 | 4/32 | 0/32 | 0/32 |
| Abdominal painGastrointestinal disorders | 0/32 | 3/32 | 0/32 | 0/32 |
| Injection site painGeneral disorders | 2/32 | 1/32 | 3/32 | 1/32 |
| DizzinessNervous system disorders | 2/32 | 3/32 | 0/32 | 0/32 |
| Vision blurredEye disorders | 0/32 | 2/32 | 0/32 | 0/32 |
| Abdominal distensionGastrointestinal disorders | 2/32 | 2/32 | 2/32 | 0/32 |
| VomitingGastrointestinal disorders | 2/32 | 0/32 | 0/32 | 0/32 |
| Injection site erythemaGeneral disorders | 2/32 | 1/32 | 2/32 | 0/32 |
| Vessel puncture site painGeneral disorders | 1/32 | 2/32 | 0/32 | 0/32 |
| HeadacheNervous system disorders | 2/32 | 0/32 | 2/32 | 0/32 |
Safety Set included all participants who received at least one dose of the study drug.
| Age, Continuous(years) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| Mean | 31.8 (20 to 41) | 32.4 (20 to 45) | 32.5 (18 to 39) | 35.9 (23 to 45) | 33.2 (18 to 45) |
| Sex: Female, Male(Participants) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| Female | 9 | 9 | 2 | 1 | 21 |
| Male | 7 | 7 | 14 | 15 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 14 | 9 | 9 | 42 |
| Not Hispanic or Latino | 6 | 2 | 7 | 7 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 | 3 | 11 |
| White | 12 | 14 | 10 | 13 | 49 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 0 | 1 | 0 | 3 |
| Region of Enrollment(Participants) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| United States | 16 | 16 | 16 | 16 | 64 |
| Height(cm) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| Mean | 163.19 (151.0 to 175.0) | 164.06 (151.0 to 177.0) | 173.81 (165.0 to 189.0) | 175.38 (163.0 to 187.0) | 169.11 (151 to 189) |
| Weight(kg) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| Mean | 64.38 (55.4 to 73.5) | 66.51 (55.8 to 73.4) | 86.39 (74.9 to 108.8) | 84.68 (75.3 to 106.8) | 75.49 (55.4 to 108.8) |
| Body Mass Index (BMI)(kg/m^2) | Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1) | Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1) | Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2) | Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2) | Total |
|---|---|---|---|---|---|
| Mean | 24.271 (19.31 to 30.72) | 24.891 (20.12 to 30.25) | 28.558 (23.98 to 31.81) | 27.530 (22.99 to 31.41) | 26.313 (19.31 to 31.81) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2021 to primary completion in Aug 2021, 7 months.
Results were first posted in Oct 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide